{"schema_version":"secwatch.filing_event.v1","accession":"0001606498-23-000018","form_type":"8-K/A","ticker":"AVNS","cik":"0001606498","company_name":"AVANOS MEDICAL, INC.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.808843+00:00","generated_at":"2026-06-19T06:58:36.585054+00:00","sec_items":["2.05","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Avanos Medical estimates $20M-$25M cash costs for transformation; expects $45M-$55M gross savings by 2025","bullets":["Cash expenses of $20M-$25M for transformation: $9M-$12M consulting/retention, $8M-$11M manufacturing/supply chain.","Employee severance and benefits costs estimated at $6M-$8M.","Anticipated savings of ~$10M in 2023; gross savings of $45M-$55M by 2025, mostly in 2024.","Plan includes combining Chronic Care and Pain franchises, exiting low-margin products, and cost management."],"urls":{"canonical":"https://secwatch.observer/filing/0001606498-23-000018","json":"https://secwatch.observer/filing/0001606498-23-000018.json","markdown":"https://secwatch.observer/filing/0001606498-23-000018.md","text":"https://secwatch.observer/filing/0001606498-23-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000018/0001606498-23-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000018/avns-20230110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T06:58:36.585054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6d0806250be826bf6f498c3db53d132a19c19cb","claim":"AVANOS MEDICAL, INC. announced a restructuring with charges of between $20.0 million and $25.0 million affecting Chronic Care and Pain franchises (between $6.0 million and $8.0 million of employee severance and benefits costs).","evidence_excerpt":"The Company now estimates it will incur between $20.0 million and $25.0 million of cash expenses in connection with the Transformation Process, consisting of between $9.0 million and $12.0 million of program management consulting and employee retention expenses; between $8.0 million and $11.0 million of expenses associated with manufacturing and supply chain improvements and portfolio rationalization; and the remainder for expenses associated with organizational design and alignment and other related activities.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1606498/000160649823000018/0001606498-23-000018-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"between $20.0 million and $25.0 million"},{"label":"Affected area","value":"Chronic Care and Pain franchises"},{"label":"Headcount","value":"between $6.0 million and $8.0 million of employee severance and benefits costs"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}